Biologics major cost driver in IBD management in the US

Biologics major cost driver in IBD management in the US PharmacoEconomics & Outcomes News 792, p7 - 2 Dec 2017 Biologics major cost driver in IBD management in the US The increasing use of biologic therapies for the treatment of inflammatory bowel disease (IBD) has a major cost impact in the US, according to researchers from Stanford University School of Medicine, US. The researchers used data from the Truven Marketscan database to assess outpatient drug use trends of IBD medications over a 9-year period (2007–2015) and associated costs. The market share of biologics relative to other IBD medications, including immunomodulators, 5-aminosalicylic-acids (5-ASAs) and oral corticosteroids, was also determined. The analysis of data for 415 405 patients with IBD showed that the proportion of patients using biologics increased nearly threefold, from 7.1% in 2007 to 20.5% in 2015. Consequently, there was a consistent rise in the market share of biologics (from 13.7% to 30.1%) and fall for both immunomodulators and 5-ASAs (from 22.7% to 16.0% and 48.6% to 39.2%, respectively). Corticosteroid-only use remained stable at approximately 15%. The per-member per-year (PMPY) costs of an average patient receiving biologic therapy increased from $US25 275 in 2007 to $36 051 in 2015, and the share of PMPY costs for biologics increased from 72.9% to 85.7%. The study also showed that the share of PMPY costs for biologics was even higher in paediatric patients with IBD (increasing from 81.7% to 94.9%). Yu H, et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Alimentary Pharmacology and Therapeutics : 22 Nov 2017. Available from: URL: http://doi.org/10.1111/apt.14430 803286173 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Biologics major cost driver in IBD management in the US

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/biologics-major-cost-driver-in-ibd-management-in-the-us-gcGcHTVwZf
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4530-6
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 792, p7 - 2 Dec 2017 Biologics major cost driver in IBD management in the US The increasing use of biologic therapies for the treatment of inflammatory bowel disease (IBD) has a major cost impact in the US, according to researchers from Stanford University School of Medicine, US. The researchers used data from the Truven Marketscan database to assess outpatient drug use trends of IBD medications over a 9-year period (2007–2015) and associated costs. The market share of biologics relative to other IBD medications, including immunomodulators, 5-aminosalicylic-acids (5-ASAs) and oral corticosteroids, was also determined. The analysis of data for 415 405 patients with IBD showed that the proportion of patients using biologics increased nearly threefold, from 7.1% in 2007 to 20.5% in 2015. Consequently, there was a consistent rise in the market share of biologics (from 13.7% to 30.1%) and fall for both immunomodulators and 5-ASAs (from 22.7% to 16.0% and 48.6% to 39.2%, respectively). Corticosteroid-only use remained stable at approximately 15%. The per-member per-year (PMPY) costs of an average patient receiving biologic therapy increased from $US25 275 in 2007 to $36 051 in 2015, and the share of PMPY costs for biologics increased from 72.9% to 85.7%. The study also showed that the share of PMPY costs for biologics was even higher in paediatric patients with IBD (increasing from 81.7% to 94.9%). Yu H, et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Alimentary Pharmacology and Therapeutics : 22 Nov 2017. Available from: URL: http://doi.org/10.1111/apt.14430 803286173 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off